ScholarLens Back to search
2018•Translational Lung Cancer ResearchOpen access

Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer

Nagio Takigawa, Nobuaki Ochi, Hiromichi Yamane

Open full text 2 citations

Abstract

Although most of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) is sensitive to EGFR tyrosine kinase inhibitor (TKI), the tumor becomes resistant to the drug after around 1 year.

Open-access reader

About this research paper

What this paper is about

Although most of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) is sensitive to EGFR tyrosine kinase inhibitor (TKI), the tumor becomes resistant to the drug after around 1 year.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Although most of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) is sensitive to EGFR tyrosine kinase inhibitor (TKI), the tumor becomes resistant to the drug after around 1 year.

Key concepts: Epidermal growth factor receptor, Lung cancer, Cancer research, Medicine, Tyrosine kinase, EGFR inhibitors, Gefitinib, Erlotinib

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer — Research Paper | ScholarLens